FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297888434> ?p ?o ?g. }

• W4297888434 abstract "Conversion therapy provides selected patients with unresectable hepatocellular carcinoma the opportunity to undergo a curative hepatectomy and achieve long-term survival. Although various regimens have been used for conversion therapy, their conversion rate and safety remain uncertain. Therefore, we conducted some meta-analyses to evaluate the efficacy and safety of several conversion regimens in order to elucidate the optimal regimen.We performed systematic literature research on PubMed, Embase, and the Web of Science until July 30, 2022. Chemotherapy, transcatheter arterial chemoembolization (TACE), molecular therapy (targeted therapy, immunotherapy, or a combination of both), and combined locoregional-systemic therapy were the conversion regimens we targeted.Twenty-four studies were included. The pooled conversion rates for chemotherapy, TACE, molecular therapy, and combined locoregional-systemic therapy were 13% (95% confidence interval [CI], 7%-20%; I² = 82%), 12% (95% CI, 9%-15%; I² = 60%), 10% (95% CI, 3%-20%; I² = 90%), and 25% (95% CI, 13%-38%; I² = 89%), respectively. The pooled objective response rates (ORR) for chemotherapy, TACE, molecular therapy, and combined locoregional-systemic therapy were 19% (95% CI, 12%-28%; I² = 77%), 32% (95% CI, 15%-51%; I² = 88%), 30% (95% CI, 15%-46%; I² = 93%), and 60% (95% CI, 41%-77%; I² = 91%), respectively. The pooled grade ≥3 AEs for chemotherapy, TACE, molecular therapy, and combined locoregional-systemic therapy were 67% (95% CI, 55%-78%; I² = 79%), 34% (95% CI, 8%-66%; I²= 92%), 30% (95% CI, 18%-43%; I² = 84%), and 40% (95% CI, 23%-58%; I² = 89%), respectively. Subgroup analyses showed the conversion rate, ORR and grade ≥3 AE rate for tyrosine kinase inhibitor (TKI) combined with immune checkpoint inhibitor (ICI) and locoregional therapy (LRT) were 33% (95% CI, 17%-52%; I² = 89%), 73% (95% CI, 51%-91%; I² = 90%), 31% (95% CI, 10%-57%; I² = 89%), respectively.Combined locoregional-systemic therapy, especially TKI combined with ICI and LRT, may be the most effective conversion therapy regimen, associated with a significant ORR, conversion potential, and an acceptable safety profile." @default.
• W4297888434 created "2022-10-01" @default.
• W4297888434 creator A5013972114 @default.
• W4297888434 creator A5033098447 @default.
• W4297888434 creator A5040599413 @default.
• W4297888434 creator A5066518893 @default.
• W4297888434 date "2022-09-13" @default.
• W4297888434 modified "2023-09-25" @default.
• W4297888434 title "Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis" @default.
• W4297888434 cites W1462373416 @default.
• W4297888434 cites W1595010482 @default.
• W4297888434 cites W1971837077 @default.
• W4297888434 cites W1991644708 @default.
• W4297888434 cites W2017044005 @default.
• W4297888434 cites W2034948111 @default.
• W4297888434 cites W2035694700 @default.
• W4297888434 cites W2040009882 @default.
• W4297888434 cites W2081362078 @default.
• W4297888434 cites W2085629594 @default.
• W4297888434 cites W2101031676 @default.
• W4297888434 cites W2103362199 @default.
• W4297888434 cites W2136462552 @default.
• W4297888434 cites W2138059780 @default.
• W4297888434 cites W2141444851 @default.
• W4297888434 cites W2280676952 @default.
• W4297888434 cites W2332011447 @default.
• W4297888434 cites W2487553606 @default.
• W4297888434 cites W2617982897 @default.
• W4297888434 cites W2766398846 @default.
• W4297888434 cites W2776693830 @default.
• W4297888434 cites W2784317233 @default.
• W4297888434 cites W2803786348 @default.
• W4297888434 cites W2938801817 @default.
• W4297888434 cites W2944033593 @default.
• W4297888434 cites W3000401463 @default.
• W4297888434 cites W3047155119 @default.
• W4297888434 cites W3099108820 @default.
• W4297888434 cites W3101856357 @default.
• W4297888434 cites W3118615836 @default.
• W4297888434 cites W3121026211 @default.
• W4297888434 cites W3128646645 @default.
• W4297888434 cites W3133992342 @default.
• W4297888434 cites W3137254944 @default.
• W4297888434 cites W3137429784 @default.
• W4297888434 cites W3149900842 @default.
• W4297888434 cites W3156288964 @default.
• W4297888434 cites W3158785061 @default.
• W4297888434 cites W3186601765 @default.
• W4297888434 cites W3195584801 @default.
• W4297888434 cites W3204422329 @default.
• W4297888434 cites W3214415684 @default.
• W4297888434 cites W4245784696 @default.
• W4297888434 doi "https://doi.org/10.3389/fonc.2022.978823" @default.
• W4297888434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36176393" @default.
• W4297888434 hasPublicationYear "2022" @default.
• W4297888434 type Work @default.
• W4297888434 citedByCount "1" @default.
• W4297888434 countsByYear W42978884342023 @default.
• W4297888434 crossrefType "journal-article" @default.
• W4297888434 hasAuthorship W4297888434A5013972114 @default.
• W4297888434 hasAuthorship W4297888434A5033098447 @default.
• W4297888434 hasAuthorship W4297888434A5040599413 @default.
• W4297888434 hasAuthorship W4297888434A5066518893 @default.
• W4297888434 hasBestOaLocation W42978884341 @default.
• W4297888434 hasConcept C121608353 @default.
• W4297888434 hasConcept C126322002 @default.
• W4297888434 hasConcept C143998085 @default.
• W4297888434 hasConcept C185926286 @default.
• W4297888434 hasConcept C2776694085 @default.
• W4297888434 hasConcept C2776999253 @default.
• W4297888434 hasConcept C2778019345 @default.
• W4297888434 hasConcept C2781230642 @default.
• W4297888434 hasConcept C2781413609 @default.
• W4297888434 hasConcept C44249647 @default.
• W4297888434 hasConcept C530470458 @default.
• W4297888434 hasConcept C71924100 @default.
• W4297888434 hasConcept C90924648 @default.
• W4297888434 hasConcept C95190672 @default.
• W4297888434 hasConceptScore W4297888434C121608353 @default.
• W4297888434 hasConceptScore W4297888434C126322002 @default.
• W4297888434 hasConceptScore W4297888434C143998085 @default.
• W4297888434 hasConceptScore W4297888434C185926286 @default.
• W4297888434 hasConceptScore W4297888434C2776694085 @default.
• W4297888434 hasConceptScore W4297888434C2776999253 @default.
• W4297888434 hasConceptScore W4297888434C2778019345 @default.
• W4297888434 hasConceptScore W4297888434C2781230642 @default.
• W4297888434 hasConceptScore W4297888434C2781413609 @default.
• W4297888434 hasConceptScore W4297888434C44249647 @default.
• W4297888434 hasConceptScore W4297888434C530470458 @default.
• W4297888434 hasConceptScore W4297888434C71924100 @default.
• W4297888434 hasConceptScore W4297888434C90924648 @default.
• W4297888434 hasConceptScore W4297888434C95190672 @default.
• W4297888434 hasLocation W42978884341 @default.
• W4297888434 hasLocation W42978884342 @default.
• W4297888434 hasLocation W42978884343 @default.
• W4297888434 hasLocation W42978884344 @default.
• W4297888434 hasOpenAccess W4297888434 @default.
• W4297888434 hasPrimaryLocation W42978884341 @default.
• W4297888434 hasRelatedWork W1900595920 @default.
• W4297888434 hasRelatedWork W1984282923 @default.

• next